Product Images Doxorubicin Hydrochloride

This appears to be a brief summary of clinical trials conducted in several countries. The trials are labeled with acronyms such as NSABP B-15 and SECSG 2. There is a mention of a boundary for non-inferiority with CMP and the statement that the effect of CMF is retained. The context and purpose of the trials are not clear.*

This is a label of a pharmaceutical product called DOXOrubicin HCI Injection. It comes in a 5 mL Single-Dose Vial with a concentration of 2mg per mL and is intended for intravenous use only. The label warns that this is a cytotoxic agent and advises to discard any unused portion. The product was manufactured in India in 2017. The rest of the text is not legible and contains some non-English characters.*

This is a description of a pharmaceutical product named DOXOrubicin. It is used as an injection to treat various conditions. The product is available in 5 mL single-dose vials and should be stored in refrigerated conditions between 2°C and 8°C. It has a concentration of 2mg per mL and is a cytotoxic agent that should be protected from light. The product carries a National Drug Code (NDC) of 70860-208-05.*

This is a cautionary label for a cytotoxic drug with the NDC code 70860-208-51, which is sold in a 100 mL multi-dose vial without preservatives or natural rubber latex. The drug contains 200 mg per 100 mL of DOXOrubicin and should be stored in the refrigerator between 2°C and 8°C (36°F to 46°F). It can only be used intravenously and is manufactured by Athenex in 2017.*